DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 11:08:26 16/07/2024 pm IST | ||
| 1.55 EUR / 1.64 EUR | +7.05% |
|
| Current month | +4.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 1.56 | +4.70% |
| 15/24/15 | 1.49 | +4.20% |
| 12/24/12 | 1.43 | +1.42% |
| 11/24/11 | 1.41 | -1.40% |
| 10/24/10 | 1.43 | +4.38% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 09:32 pm IST
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | PUT |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG5ZZH |
| ISIN | DE000MG5ZZH5 |
| Date issued | 17/06/2024 |
| Strike | 250 $ |
| Maturity | 21/03/2025 (248 Days) |
| Parity | 10 : 1 |
| Emission price | 0.94 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.56 € |
|---|---|
| Lowest since issue | 1.35 € |
| Spread | 0.07 € |
| Spread % | 4.29% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Certificates
- Certificat
